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Abstract The newly proposed criteria for diagnosing
gestational diabetes will result in a gestational diabetes
prevalence of 17.8%, doubling the numbers of pregnant
women currently diagnosed. These new diagnostic criteria
are based primarily on the levels of glucose associated with
a 1.75-fold increased risk of giving birth to large-for-
gestational age infants (LGA) in the Hyperglycemia
Adverse Pregnancy Outcome (HAPO) study; they use a
single OGTT. Thus, of 23,316 pregnancies, gestational
diabetes would be diagnosed in 4,150 women rather than in
2,448 women if a twofold increased risk of LGAwere used.
It should be recognised that the majority of women with
LGA have normal glucose levels during pregnancy by these
proposed criteria and that maternal obesity is a stronger
predictor of LGA. The expected benefit of a diagnosis of
gestational diabetes in these 1,702 additional women would
be the prevention of 140 cases of LGA, 21 cases of
shoulder dystocia and 16 cases of birth injury. The
reproducibility of an OGTT for diagnosing mild hyper-
glycaemia is poor. Given that (1) glucose is a weak
predictor of LGA, (2) treating these extra numbers has a
modest outcome benefit and (3) the diagnosis may be
based on a single raised OGTT value, further debate
should occur before resources are allocated to implementing
this change.
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Abbreviations
ACHOIS Australian Carbohydrate Intolerance Study in
Pregnant Women
GDS Gestational diabetes screen
HAPO Hyperglycemia Adverse Pregnancy Outcome
IADPSG International Association of Diabetes in
Pregnancy Study Groups
LGA Large-for-gestational age infants
MFMU Maternal–Fetal Medicine Units Network
RCT Randomised control trial
Introduction
Agreeing on the diagnostic cut-offs for gestational diabetes
remains problematic. The International Association of
Diabetes in Pregnancy Study Groups (IADPSG) recently
published a consensus derived from the Hyperglycemia
Adverse Pregnancy Outcome (HAPO) study data, suggest-
ing that all pregnant women without known diabetes should
have a 75 g OGTT at 24–28 weeks gestation [1].
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DOI 10.1007/s00125-010-2005-4Gestational diabetes would be diagnosed if one or more
values met or exceeded the following levels of glucose:
fasting 5.1 mmol/l, 1 h post glucose 10.0 mmol/l and 2 h
post glucose 8.5 mmol/l. Use of these criteria will result in
17.8% of the pregnant population being diagnosed with
gestational diabetes. A detailed analysis of the same HAPO
study information and other recent related publications
raises issues that are worthy of further debate in the wider
diabetes community.
Observational data
HAPO was an international prospective observational study
of 23,316 pregnant women directed to answer the question:
‘Is hyperglycaemia during pregnancy, at a level below that
for overt diabetes, associated with increased risk of
maternal or fetal complications?’ [2]. The participating
women had an OGTT and were divided into seven glucose
categories. The category 3 group encompassed the mean
glucose values, i.e. fasting 4.5 mmol/l, 1 h post OGTT
7.4 mmol/l and 2 h post OGTT 6.2 mmol/l, while the new
proposed cut-offs from IADPSG fall in category 5. The
primary endpoints were large-for-gestational age infants
(LGA), primary Caesarean section rate, neonatal hypogly-
caemia and cord C-peptide. The study demonstrated a
continuous relationship between glycaemia (fasting, and 1
or 2 h post glucose load) and each of the primary outcomes,
having adjusted for field centre and ethnicity. While
supporting the Pedersen hypothesis [3], the results did not
show any inflection point indicating clearly increased risk
of any of these outcomes with a particular glucose category;
rather, risk increased gradually over the glucose range.
A further publication from the group examined the role
of maternal BMI with the same primary outcomes [4]. This
report used an adjustment (Model 1) for many of the
expected confounders (age, alcohol, smoking, sex etc.), and
also a model (Model 2) that adjusted for fasting plasma
glucose and mean arterial pressure. The OR for LGA,
primary Caesarean section and cord C-peptide increased
significantly for increasing categories of BMI, this differ-
ence being maintained when adjusted for glucose and mean
arterial pressure (reference group BMI <22.6 kg/m
2;
Fig. 1a). When the plot for LGA vs glucose is added
(reference group category 1 glucose as used in the HAPO
report; Fig. 1a), it is apparent that maternal BMI has a
greater impact on OR than maternal glucose in all except
the highest glucose category. This is also true for the
primary Caesarean section rate (Electronic supplementary
material [ESM] Fig. 1a), whereas the glucose level had
more influence on the OR for cord C-peptide in glucose
categories 5–7 (ESM Fig. 1b). Thus, maternal BMI and
glucose both contribute to risk of LGA, but the role of BMI
was more pronounced than that of glucose in determining
LGA incidence, until the highest glucose category was
reached. Using the category BMI 22.6–28.4 kg/m
2 (which
includes overweight women) and category 3 for glucose as
the reference groups (i.e. using reference groups that
include the means) shows that BMI and glucose have a
similar impact on the OR (ESM Fig. 2a–c).
The majority of women from the HAPO data had
glucose levels ≤category 3, i.e. the category encompassing
the mean glucose level (Fig. 1b). Moreover, the number of
LGA increased proportionately with higher glucose levels
(Fig. 1b), but when the numbers of mothers with LGA in
given glucose categories are classed separately (Fig. 1c),
the majority (63%) of women with LGA are seen to have
glucose levels from the OGTT at or lower than category 3,
the category incorporating the mean glucose level. This is
also true for the 1 and 2 h post-load challenge (ESM
Fig. 3). It is also noteworthy that at category 5 (equivalent
to the IADPSG cut-off criteria, accepting that some cases in
category 5 will lie above these cut-offs within category 5)
women below these cut-offs who had LGA represented
78% of all women giving birth to LGA.
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Fig. 1 a Relationship of the OR for an infant of birthweight >90th
percentile vs the BMI in categories (reference group BMI <22.6 kg/m
2
[4]) or maternal fasting glucose in categories from HAPO (diamonds;
reference group category 1 lowest glucose [2]). a The BMI
relationship is adjusted for model 1 (circles) or model 2 (triangles)
(see text for details). The relationship for maternal fasting glucose
categories is also shown (black diamonds). b Number of participants
in each category of glucose in HAPO (white bars), with number of
mothers with LGA infants (black bars). c Number of participants in
each category of glucose who had LGA infants
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and glucose predict LGA. However, BMI is more relevant at
allbutthehighestglucoselevelsandmostcasesofLGAoccur
in the presence of normal maternal glycaemia. A large
prospective study from Spain found that the upper quartile
of maternal BMI was responsible for 23% of macrosomia,
while gestational diabetes accounted for 3.8% [5]. Of course,
an interrelation between BMI and glucose is not precluded.
Interventional studies
There are two major randomised control trials (RCTs) and a
meta-analysis addressing whether controlling glucose in
gestational diabetes is of value [6–8]. The Australian
Carbohydrate Intolerance Study in Pregnant Women
(ACHOIS) [6] had a composite endpoint of fetal death,
bone fracture, shoulder dystocia and nerve palsy. The
Maternal–Fetal Medicine Units network (MFMU) [7] study
also had a composite, albeit slightly different endpoint,
namely fetal death, birth trauma, hyperbilirubinaemia,
neonatal hypoglycaemia or hyperinsulinaemia. Both studies
randomised approximately 1,000 patients to therapy or
observation, were well conducted and formed the back-
bone of the meta-analysis. Both studies also had a two step
approach to diagnosis with risk factors/gestational diabetes
screen (GDS) in ACHOIS or GDS alone in the MFMU.
The ACHOIS showed a significant decreased risk in the
composite outcome, whereas the MFMU study composite
outcome was not significantly altered. However, in both
studies the incidence of LGA was decreased significantly,
while shoulder dystocia was significantly decreased in the
MFMU, but not in the ACHOIS study, and birth injury was
not significantly decreased in either study. In both of the
RCTs, maternal weight gain from diagnosis to term was
significantly lower in the interventional groups (mean
1.7 kg less in ACHOIS, 2.2 kg less in the MFMU study).
A recent meta-analysis assessed the benefits from inter-
ventionsforgestationaldiabetesintermsofperinatalandlong-
term outcomes [8]. In the primary intervention studies, of all
perinatal issues only LGA/macrosomia and shoulder dystocia
were significantly reduced by intervention, with a trend for
decreased birth trauma (OR 0.39, 95% CI 0.13–1.15). In the
comparison of intensive vs less intense care, only shoulder
dystocia was significantly diminished by intervention, with
no significant change in LGA/macrosomia or birth trauma.
At this juncture the evidence indicates that treating
gestational diabetes decreases LGA and shoulder dystocia,
which provides a trend towards a decrease in birth injury.
IADPSG process and outcomes
The IADPSG convened in Pasadena (CA, USA) to develop
a consensus as to what level of less severe hyperglycaemia
is important and at what level of glucose gestational
diabetes should be diagnosed. This was in the context of
the US Preventative Services Task Force and a UK report
questioning the value of screening for gestational diabetes
[9, 10]. The HAPO results were reviewed, and other studies
and long-term outcomes were noted, followed by recent
publication of the consensus panel recommendations [1].
Important outcomes were deemed to be birthweight, cord
C-peptide and per cent body fat in the neonate >90th
percentile. The reference point taken was the outcome for
the group associated with mean glucose in the OGTT
(4.5 mmol/l fasting, 7.4 mmol/l 1 h post challenge, and
6.2 mmol/l 2 h post challenge). There was prolonged
discussion about the OR relative to the mean that was
considered to be important: for example, was a 1.5-, 1.75-
or twofold increased risk of these outcomes damaging
enough to warrant the diagnosis of gestational diabetes?
The consensus group decided on a 1.75-fold increased risk
threshold, giving cut-offs of 5.1, 10.0 and 8.5 mmol/l for
fasting, and 1 and 2 h post-challenge glucose respectively,
with a diagnosis of gestational diabetes being made if one
of these values was met or exceeded. These values fell
within category 5 of the original HAPO groupings. A
twofold increased risk gave values of 5.3, 10.6 and
9.0 mmol/l for fasting, and 1 and 2 h post-challenge
glucose respectively (data provided at Pasadena meeting),
and fell in category 6 of the original HAPO study data for
the fasting and 2 h values, and close to the upper boundary
of category 5 for the 1 h value (9.6–10.7 mmol/l).
As published, the IADPSG criteria cut-offs give rise to an
overall gestational diabetes prevalence of 17.8% (with some
regional variation). As a result, 8.3% of women would be
diagnosed on the basis of fasting glucose ≥5.1 mmol/l, a
further 5.7% would be diagnosed on the basis of 1 h post-
challenge glucose ≥10.0 mmol/l and 2.1% would be diag-
nosed on the basis of a 2 h post-challenge value ≥8.5 mmol/l.
A further 1.7% of the women in HAPO were excluded at the
start because their glucose values were markedly elevated, i.e.
fasting values > 5.8 mmol/l or 2 h levels >11.1 mmol/l. If the
twofold increased risk cut-offs were used, 8.8% would be
diagnosed by OGTT for a total of 10.5% including the
markedly hyperglycaemic group.
The IADPSG consensus suggested a single 75 g OGTT
at weeks 24–28 of gestation. Testing in earlier pregnancy
for overt diabetes was recommended in populations with a
high prevalence of diabetes, with determination of
fasting plasma glucose, HbA1c or random glucose. Overt
diabetes may be diagnosed in pregnancy at fasting
glucose values of ≥7.0 mmol/l, HbA1c ≥6.5% or random
glucose ≥11.1 mmol/l, the latter needing to be confirmed
by one of the former. If fasting glucose in early pregnancy
is ≥5.1 mmol/l, the woman is diagnosed with gestational
diabetes.
482 Diabetologia (2011) 54:480–486Impact of criteria
ThetwomajorinterventionRCTstudies[6, 7] showed a mean
occurrence of 18.25% LGA in controls, reduced to 10.05%
with therapy, with a corresponding occurrence of 3.5%
shoulder dystocia (reduced to 1.25% with therapy) and birth
injury reduced from 1.03% to 0.3%. Applying this informa-
tion to HAPO data gives some indication of the impact of
intervention given the different cut-offs for diagnosis.
In HAPO there were 2,221 cases of LGA. If category 5
had been usedas acut-offfordiagnosing gestational diabetes
(approximating the IADPSG cut-offs), then 491 potential
cases ofLGAwouldhavebeen identified, treatmentofwhich
would have been expected to prevent 221 cases. If category 6
had been used as cut-off, fewer potential cases of LGA
overall would have been diagnosed (181), with proportion-
ally fewer cases prevented (81) (Table 1).
Translating this to the more important outcomes of
shoulder dystocia [11] and birth injury, in HAPO 212 cases
of shoulder dystocia and 139 cases of birth injury occurred.
Using the adjusted OR of 1.18 for fasting maternal
glycaemia and the risk of shoulder dystocia/birth injury
[2], 108 cases of shoulder dystocia would have been
identified at category 5 diagnostic cut-offs, of which 69
would have been prevented by intervention. At category 6,
some 75 cases of shoulder dystocia would have been found
and 48 cases prevented. Using category 5 diagnostic cut-
offs, 70 cases of birth injury would be indentified, of which
50 would be prevented, while at category 6 the numbers
would be 48 and 34, respectively (Table 1).
Thus using the IADPSG report based on HAPO data of
23,316 pregnant women, 4,150 cases of gestational diabetes
would be diagnosed with the new criteria based on an OR
risk for adverse outcomes of 1.75 and equivalent to
category 5 cut-offs vs 2,448 cases based on an OR risk
for adverse outcomes of 2.0, equivalent to category 6 cut-
offs. This would result in prevention of 221 vs 81 cases of
LGA, 69 vs 48 cases of shoulder dystocia and 50 vs 34
cases of birth injury. Thus at a cost of diagnosing and
treating an extra 1,702 cases of gestational diabetes, one
might expect to avoid 140 cases of LGA, 21 cases of
shoulder dystocia and 16 cases of birth injury. It should be
debated whether diagnosing this many extra women with
gestational diabetes is worth this benefit.
Long-term risks to the offspring of gestational diabetes
Hyperglycaemia in utero is associated with increased
insulin resistance and hyperglycaemia in offspring as
described in animal studies [12–14]. Some human studies
suggest similar outcomes, a risk cited as an additional
argument for diagnosing more gestational diabetes, since
diagnosing and treating gestational diabetes may decrease
obesity and diabetes in the long-term. Hillier et al.
demonstrated that excess obesity in the offspring of women
with gestational diabetes was ameliorated by therapy [15].
However, maternal weight was not available to assess the
role of maternal obesity. Previous studies have shown
increased obesity in teenage offspring of women exposed to
hyperglycaemia vs siblings of the same women who were
not exposed to hyperglycaemia [16], but other studies in
Pima Indians showed that this impact on offspring weight
was lost in older offspring aged 20–24 years [17]. A
prospective longitudinal study showed that the occurrence
of gestational diabetes had no impact on obesity rates in 16-
year-old offspring in the absence of maternal obesity [18].
HAPO data for offspring at age 2 showed no relationship
between offspring weight and maternal glycaemia level
during pregnancy [19]. Follow-up of children at 4–5 years
old from the ACHOIS trial failed to show a difference in
BMI z scores between offspring of intervention and control
gestational diabetes mothers, despite the former having a
reduced macrosomic rate at birth [20], although it may be
too early to see any epigenetic effects. Most offspring of
women with type 1 diabetes are exposed to much more
severe hyperglycaemia in utero than offspring of women
with gestational diabetes, yet the increased risk of glucose
intolerance in the offspring of women with type 1 diabetes
Table 1 Frequency of women with LGA whose infants experienced shoulder dystocia or birth injury
All cases Category 5
a Category 6
b
Condition n Identified (n) Prevented (n)
c Identified (n) Prevented (n)
c
LGA 2,221 491 221 181 81
Shoulder dystocia 212 108 69 75 48
Birth injury 139 70 50 48 34
Data are based on 23,316 participants in HAPO [2]
aNumbers equate with proposed criteria for gestational diabetes by IADPSG [1]
bNumbers equate with those from using glucose criteria associated with a twofold increased risk of adverse fetal outcome
cDerived from the mean expected benefit from the two major prospective outcome studies in the treatment of gestational diabetes [6, 7]
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gestational diabetes, with no associated difference in
offspring BMI [21]. Offspring of type 1 diabetic women
were less overweight than those of mothers who had
gestational diabetes [22]. These studies indicate that hyper-
glycaemia in utero plays some role in adult offspring
glucose tolerance and obesity, but that other factors are
more important.
Long-term risks of gestational diabetes for the mother
Since gestational diabetes is associated with insulin
resistance and a beta cell defect, features that are evident
in the postpartum state [23], identifying gestational diabetes
allows recognition of a group at increased risk in the long
term of developing diabetes [24]. Such labelling opens the
possibility that these women may be targeted for interven-
tion to prevent diabetes in the future. While high rates of
diabetes are common in women with a history of
gestational diabetes, these studies used criteria with higher
historical glucose thresholds for the diagnosis of gestational
diabetes, and extrapolating the same frequency for the
development of diabetes using the newer proposed values is
likely to lead to an overestimation.
Negative outcomes
Diagnosing gestational diabetes has cost implications. While
some diabetes organisations specifically exclude a cost–
benefit analysis when determining guidelines [25], major
expenses occur when diagnosing more cases, especially
when they may translate into decreased opportunity costs
for other aspects of diabetes, e.g. type 2 diabetes in
pregnancy. Increased costs include those associated with
care from nurses, dietitians and physicians, as well as with
glucose monitoring and therapy of the diabetes [26].
Although the Caesarean section rate decreased in the
MFMU study [7], treatment of gestational diabetes does
not always decrease the Caesarean section rate [6, 27].
Several centres have developed policies that dictate
delivery protocols for women diagnosed with gestational
diabetes, particularly those who have been started on
insulin regardless of glycaemic control achieved or fetal
size. Finally, and perhaps most importantly, there are
labelling costs for the individual diagnosed with gestational
diabetes in terms of their care and future insurability.
Other considerations
Other issues that the IADPSG proposals raise include the
concern that the OGTT itself is poorly reproducible [28,
29], particularly in this intermediate zone of impaired
glucose tolerance [30, 31]. Thus, diagnosing individuals
on the basis of one test, with a single abnormal value that
on repeat could well be normal, needs to be debated. The
criteria proposed are derived from HAPO data collected at
24–28 weeks of gestation, yet the consensus panel
proposed that the fasting criteria should be used for
diagnosing gestational diabetes in early pregnancy, before
fetal and hormonal changes of pregnancy have had an
impact. Thus a woman with fasting glucose of 5.1 mmol/l
at 7 weeks gestation would be diagnosed as having
gestational diabetes, but in the non-pregnant state this value
would be considered perfectly normal!
On the positive side it must be acknowledged that
diagnosing and treating gestational diabetes, in addition to
the benefits outlined above, is also associated with less
preeclampsia, gestational hypertension, obstetrical interven-
tions and maternal health issues [6, 7]. However, the question
of whether these positive outcomes relate to treatment of
glycaemia or less weight gain remains unanswered. The
proposed IADPSG diagnostic criteria are not based on a
composite of these benefits, they are based on LGA, cord
C-peptide and fetal adiposity, and for LGA the BMI level
may be a better predictor than glucose alone [5, 32].
Where does this leave us?
The increased diagnostic rate of 17.8% using the IADPSG
criteria would only prevent 140 cases of LGA and 16 cases
of birth injury out of a total denominator group of 23,316
pregnancies. Yet 78% of cases of LGA will be born to
women not diagnosed according to these criteria, as
maternal obesity is a stronger predictor of LGA than
maternal glycaemia in HAPO glucose categories 1–6 and
the reduced LGA rates with treatment of gestational
diabetes could be due to the lower weight gain in the
interventional groups; moreover, a single abnormality in an
OGTT may not be reproducible.
Serious hyperglycaemia during pregnancy requires
identification and therapy. For women with milder
hyperglycaemia the benefits of therapy are so modest
that the cost–benefit relation of proposed diagnostic cut-
offs have to be considered. Identifying women with
increased risk of later diabetes has an undetermined
benefit. At the same time, the value of treating
gestational diabetes, independently of maternal weight,
with a view to the long-term well-being of the offspring
has not been established. The cut-offs associated with a
twofold increased risk of LGA deserve consideration.
They would give a prevalence of 10.5% for gestational
diabetes, similar to the prevalence of diabetes in the
general population [33], and are close to the values
currently used for gestational diabetes diagnosis in Canada.
Thus 75 g OGTT criteria derived from a twofold increased
risk of LGA in HAPO, i.e. fasting glucose ≥5.3 mmol/l, 1 h
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challenge glucose ≥9.0 mmol/l, may be a reasonable
starting point. Since in the HAPO study each glucose cut-
off level from the OGTT was associated with adverse
outcomes, one elevated value should be sufficient for
diagnosis. A diagnosis of diabetes typically requires the
test be confirmed, unless elevation of glucose level is
unequivocal. Continued use of the GDS 50 g screen may
satisfy this need, and a two-step procedure was more cost-
effective than the universal OGTTapproach in the analysis
by the National Institute for Health and Clinical Excellence
[26]. Furthermore, setting upper limits for the GDS to
diagnose gestational diabetes simplifies the approach [34]
with proven cost-effectiveness [35]. In time, the use of the
50 g test in this manner would have to be validated.
Thus a proposal for the diagnosis of gestational
diabetes could be that all pregnant women without a
diagnosis of diabetes should have a 50 g glucose load
between 24 and 28 weeks of gestation, without regard to
fasting and with determination of plasma glucose 1 h later.
The findings should then be interpreted as follows: (1) a
value of ≥11.1 mmol/l would merit a diagnosis of
gestational diabetes; (2) values of 7.8–11.0 mmol/l would
warrant conducting a 75 g OGTT, with OGTT cut-offs at
5.3 mmol/l fasting, 10.6 mmol/l 1 h post-challenge and
9.0 mmol/l 2 h post challenge, one of which would be
sufficient for diagnosis if equalled or exceeded; and (3) a
value of <7.8 mmol/l would indicate that gestational
diabetes is not present.
Using such criteria would diagnose the more severe
forms of gestational diabetes and give a diagnosis of
gestational diabetes in about 10% of the pregnant popula-
tion, with gestational diabetes associated with a twofold
increased risk of adverse outcomes for the baby; it would
also involve two steps to help overcome the reproducibility
issues of a one-off OGTT.
While LGA and associated birth injury are related to
hyperglycaemia, it appears probable that maternal weight or
weight gain plays a more important role for most women.
Markedly increasing the number of women diagnosed with
gestational diabetes is likely to be an inefficient way of
dealing with the problem of LGA. The resources saved by
not having an extra 8% of the population diagnosed with
gestational diabetes would be better spent on women with
pre-existing diabetes in pregnancy. Future research, hope-
fully, will lead us to what really causes unexplained LGA.
Glucose contributes, but with three quarters of LGA infants
born to women with normal glucose tolerance, it is clearly
not the whole story.
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